Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Update on AGM Procedure

8 Apr 2020 07:00



Update on AGM Procedure

LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides an update on its upcoming Annual General Meeting (“AGM”), scheduled to be held at the offices of Shakespeare Martineau at 60 Gracechurch Street, London EC3V 0HR, United Kingdom at 10.30 a.m. on April 16, 2020.

The Company currently plans to hold its AGM as scheduled, however given the UK Government’s present restrictions on public gatherings of more than two people, the Board requests shareholders to vote by proxy rather than attend the AGM in person. Any shareholders seeking to attend the AGM in person will be refused entry.

By way of reminder, the deadline for delivery of completed proxy forms by holders of the Company’s ordinary shares is 10.30 a.m. on April 14, 2020. The equivalent deadline for proxy voting by holders of the Company’s American Depository Shares is 10 a.m. on April 9, 2020.

Verona Pharma continues to review the UK Government’s restrictions and recommends that shareholders monitor the Company's website and announcements for any updates in relation to the AGM. In the event that its AGM arrangements have to change, the Company will issue a further communication via a regulatory information service.

A copy of our AGM Notice and Annual Report are available on the Company’s website within the Investors section, www.veronapharma.com.

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Victoria Stewart, Director of Communicationsinfo@veronapharma.com
  
N+1 SingerTel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance)Tom Salvesen (Corporate Broking) 


Date   Source Headline
4th Oct 201312:06 pmPRNPlacing of shares
30th Sep 20137:00 amPRNHalf-yearly Report
23rd Sep 20137:00 amPRNNotice of Results
10th Sep 20137:00 amPRNClinical data presented at ERS
5th Sep 20137:01 amPRNPresentations at ERS
5th Sep 20137:00 amPRNAppointment of Richard Bungay as CFO
29th Jul 201310:13 amPRNGrant of Options
25th Jul 20131:23 pmPRNDirector Shareholding
24th Jul 20135:58 pmPRNHolding(s) in Company
23rd Jul 201312:45 pmPRNDirector Shareholding
24th Jun 20137:00 amPRNFirst patient dosed in clinical trial for VRP700
3rd Jun 20134:46 pmPRNResult of AGM
21st May 20134:00 pmPRNATS Tuesday Presentation
20th May 20137:00 amPRNATS Sunday Poster Presentations
16th May 20137:00 amPRNPresentations at ATS Conference
9th May 20138:05 amPRNPosting of Annual Report and AGM Notice
29th Apr 20137:00 amPRNNew Clinical and Scientific Advisory Board Announced
26th Apr 201310:17 amPRNDirector/PDMR Shareholding
15th Apr 20133:01 pmPRNGrant of Options
10th Apr 20133:07 pmPRNDirector's Dealing
10th Apr 201310:23 amPRNDirector Dealings
10th Apr 20137:00 amPRNFinal Results
19th Mar 20131:56 pmPRNHolding(s) in Company
5th Mar 20137:00 amPRNRPL554 demonstrates airway anti-inflammatory activity
28th Feb 20137:00 amPRNTotal Voting Rights
21st Feb 20132:35 pmPRNHolding(s) in Company
18th Feb 20132:53 pmPRNResult of General Meeting
31st Jan 201310:54 amPRNPlacing and Equity Finance Facility
24th Jan 20132:09 pmPRNNotice of Interest
18th Jan 201310:18 amPRNHolding(s) in Company
4th Jan 20132:59 pmPRNStatement Regarding Share Price Movement
12th Nov 201211:38 amPRNNotice of Interest
15th Oct 20122:01 pmPRNDirector Shareholding
12th Oct 20129:00 amPRNRPL554 Phase I/IIa data presented at ISAF 2012
26th Sep 20129:00 amPRNInvestor Presentation
17th Sep 201210:44 amPRNNew Option Scheme and Grant of Options
14th Sep 20127:00 amPRNHalf-yearly Report
6th Sep 20127:00 amPRNNotice of Interim Results
4th Sep 20127:30 amPRNVerona Pharma: RPL554 COPD Data Presented at ERS
3rd Sep 20129:30 amPRNNotice of Interest
28th Aug 20127:00 amPRNUS Patent Granted for Verona Pharma's RPL554
9th Jul 20127:00 amPRNVerona Pharma Investigates Anti-inflammatory - RPL554
1st Jun 20126:14 pmPRNResult of AGM
1st Jun 201211:30 amPRNCEO's Statement to Annual General Meeting
8th May 20124:56 pmPRNPosting of Annual Report
1st May 20127:00 amPRNVerona Pharma appoints new CEO
5th Apr 20127:00 amPRNVerona Pharma - Preliminary Unaudited Results
9th Mar 20127:00 amPRNVerona Pharma â€" First UK RPL554 anti-inflammatory trial
31st Jan 20127:00 amPRNTotal Voting Rights
16th Jan 201212:19 pmPRNNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.